Atozyle R Tablet contains Atazanavir 300mg and Ritonavir 100mg, a clinically established boosted antiretroviral combination used for managing HIV-1 infection. Ritonavir enhances the blood levels of Atazanavir, allowing stronger viral suppression and more effective long-term management of the condition. This combination is a preferred choice in many HIV treatment regimens due to its powerful, sustained action.
The formulation helps reduce viral load, improves immune function, and prevents the progression of HIV. Its boosting mechanism ensures optimal drug concentration with once-daily dosing, improving adherence and treatment outcomes. Healthcare providers frequently rely on this fixed-dose combination for both new and continuing HIV patients due to its reliability and proven clinical effectiveness.
Atozyle R Tablet is an essential product for HIV clinics, ART centers, government health programs, and pharmacies that cater to chronic care needs. Since HIV treatment is lifelong, this combination attracts consistent prescriptions and ongoing demand, making it a staple product for the antiretroviral therapy segment. Stocking it ensures better patient coverage and timely treatment continuity.
For suppliers, distributors, and exporters, Atozyle R Tablet offers strong business potential through bulk supply, institutional tie-ups, export opportunities, and third-party manufacturing collaborations. Its high clinical relevance, continuous market need, and essential status in HIV management make it a valuable and profitable addition to any antiviral portfolio.